Showing results (421-430 of 439) with videos related to
Sort By:
Pageof 44
Cancer Prevention Research (Philadelphia, Pa.)|August 31, 2017
Tobacco-Specific Carcinogens Induce Hypermethylation, DNA Adducts, and DNA Damage in Bladder CancerFeng Jin, Jose Thaiparambil, Sri Ramya Donepudi, et al.The Journal of Urology|December 17, 2021
Durability of Response to Primary Chemoablation of Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final ReportSurena F Matin, Phillip M Pierorazio, Nir Kleinmann, et al.Bladder Cancer (Amsterdam, Netherlands)|March 4, 2025
Summary from the NCI clinical trials planning meeting on next generation of clinical trials in non-muscle invasive bladder cancer<sup></sup>Andrea Apolo, Brian C Baumann, Hikmat Al-Ahmadie, et al.The Lancet. Oncology|July 8, 2020
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trialNir Kleinmann, Surena F Matin, Phillip M Pierorazio, et al.European Urology|April 10, 2017
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant ChemotherapyRoland Seiler, Hussam Al Deen Ashab, Nicholas Erho, et al.Bladder Cancer (Amsterdam, Netherlands)|July 5, 2016
Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder CancerSeth P Lerner, Dean F Bajorin, Colin P Dinney, et al.Bladder Cancer (Amsterdam, Netherlands)|July 12, 2024
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder CancerElaine Chang, Noah M Hahn, Seth P Lerner, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 11, 2025
End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder CancerAndrea Necchi, Matthew D Galsky, Nazli Dizman, et al.The Journal of Urology|May 5, 2024
Efficacy of Intravesical Nadofaragene Firadenovec for Patients With Bacillus Calmette-Guérin-Unresponsive Nonmuscle-Invasive Bladder Cancer: 5-Year Follow-Up From a Phase 3 TrialVikram M Narayan, Stephen A Boorjian, Mehrdad Alemozaffar, et al.Cell|October 10, 2017
Comprehensive Molecular Characterization of Muscle-Invasive Bladder CancerA Gordon Robertson, Jaegil Kim, Hikmat Al-Ahmadie, et al.Pageof 44